vorinostat

You have access
¹⁸F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer
Lanell M. Peterson, Brenda F. Kurland, Fengting Yan, Alena Novakova- Jiresova, Vijayakrishna K. Gadi, Jennifer M. Specht, Julie R. Gralow, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Janet F. Eary, David A. Mankoff and Hannah M. Linden

Journal of Nuclear Medicine February 1, 2021, 62 (2) 184-190; DOI: https://doi.org/10.2967/jnumed.120.244459
You have access
TBCRC 008: Early Change in ¹⁸F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer
Roisin M. Connolly, Jeffrey P. Leal, Matthew P. Goetz, Zhe Zhang, Xian C. Zhou, Lisa K. Jacobs, Joyce Mhlanga, Joo H O, John Carpenter, Anna Maria Storniolo, Stanley Watkins, John H. Fetting, Robert S. Miller, Kostandinos Sideras, Stacie C. Jeter, Bridget Walsh, Penny Powers, Jane Zorzi, Judy C. Boughey, Nancy E. Davidson, Lisa A. Carey, Antonio C. Wolff, Nagi Khouri, Edward Gabrielson, Richard L. Wahl and Vered Stearns

Journal of Nuclear Medicine January 1, 2015, 56 (1) 31-37; DOI: https://doi.org/10.2967/jnumed.114.144741

Main menu